|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 92 No. 6 (September 15), 1998:
pp. 2041-2052
Apoptotic Regulation in Primitive Hematopoietic Precursors
Rowayda Peters,
Serge Leyvraz, and
Lucien Perey
From the Centre Pluridisciplinaire d'Oncologie, University Hospital
(CHUV), Lausanne, Switzerland.
Bcl-2 and bcl-xL function as suppressors of programmed
cell death. The expression of bcl-2 protein in vivo is associated with long-lived hematopoietic cells such as mature lymphocytes and early
myeloid progenitors. Bcl-xL, a homologue of bcl-2, is also expressed in lymphocytes and thymocytes. In contrast, the bcl-2-related proteins (bax, bad, and bak) act by promoting apoptotic cell death as
shown from their expression in hematopoietic cell lines. We analyzed
the expression of bcl-2 and bcl-x proteins in hematopoietic precursors
obtained from various cell sources in adult mobilized peripheral blood
collected from 13 patients with solid tumors, 8 adult bone marrow, and
12 umbilical cord blood. The analysis was based on the expression of
the proliferation and activation specific antigens, CD38 and class II
(HLA-DR). Similarly, we analyzed the expression of bcl-2-related
proteins bcl-xL, bax, bad, and bak before and during
ex-vivo expansion. Hematopoietic precursors expressing strongly the
CD34 antigen (CD34s+) and lacking CD38 or HLA-DR
expression were analyzed by using three-color immunofluorescence
staining. The majority of CD34+ cells expressed bcl-2 and
unexpectedly showed a bimodal distribution of low and high expression.
More cells that lacked or expressed low density CD38 expressed low
bcl-2 than the more differentiated counterparts (those with high
density CD38). Immaturity (ie, little or no HLA-DR) is associated with
the expression of low bcl-2 compared with HLA-DR+.
However, HLA-DR /low population contained a lower number
of cells expressing low bcl-2 (30% to 40%) than
CD38/low in comparable samples. The hematopoietic
precursors with bcl-2low and bcl-2high formed a
homogeneous population of undifferentiated lymphoid-like cells having a
similar forward scatter. These cells expressed strongly the
bcl-xL protein (>95%) but were bax low (4% to 12%), bad low (0% to 0.8%), and bak low (0% to 3%). The expression of apoptosis specific protein (ASP) was also low (3.4% ± 3.1%) as was
Annexin V. In addition, the CD34+/CD38
showed low cell cycle activity (<2.2%). Induction of apoptosis by
overnight incubation of CD34 cells in serum-deprived medium resulted in
the upregulation of bcl-2 as a single population histogram. Thus, these
results suggest that in quiescent hematopoietic precursors, the bcl-2
protein plays a less prominent role as a survival promoter than
bcl-xL and that the low bcl-2 expression did not promote apoptosis. During day 10 of ex vivo expansion of CD34+
cells in liquid culture containing stem cell factor, interleukin-3 (IL-3), IL-6, IL-1 , and erythropoietin, the
CD34+/CD38 cells expressed high bcl-2 as a
single population histogram, and greater than 90% were
bcl-xL high. However, the expression of pro- and apoptotic
antigens increased: bax (10% to 15%), bad (5% to 8%), bak (6% to
14%), and ASP (6% to 10%). These results show the importance of
monitoring the expression of these proteins when defining the culture
conditions for ex vivo expansion.
© 1998 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Sekulic, P. Haluska Jr, A. J. Miller, J. G. De Lamo, S. Ejadi, J. S. Pulido, D. R. Salomao, E. C. Thorland, R. G. Vile, D. L. Swanson, et al.
Malignant Melanoma in the 21st Century: The Emerging Molecular Landscape
Mayo Clin. Proc.,
July 1, 2008;
83(7):
825 - 846.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Rezzoug, Y. Huang, M. K. Tanner, M. Wysoczynski, C. L. Schanie, P. M. Chilton, M. Z. Ratajczak, I. J. Fugier-Vivier, and S. T. Ildstad
TNF-{alpha} Is Critical to Facilitate Hemopoietic Stem Cell Engraftment and Function
J. Immunol.,
January 1, 2008;
180(1):
49 - 57.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
U. Ganapati, H. T. Tan, M. Lynch, M. Dolezal, S. de Vos, and J. C. Gasson
Modeling Notch Signaling in Normal and Neoplastic Hematopoiesis: Global Gene Expression Profiling in Response to Activated Notch Expression
Stem Cells,
August 1, 2007;
25(8):
1872 - 1880.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Real, Y. Cao, R. Wang, Z. Nikolovska-Coleska, J. Sanz-Ortiz, S. Wang, and J. L. Fernandez-Luna
Breast Cancer Cells Can Evade Apoptosis-Mediated Selective Killing by a Novel Small Molecule Inhibitor of Bcl-2
Cancer Res.,
November 1, 2004;
64(21):
7947 - 7953.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. G. Kayali, K. Van Gunst, I. L. Campbell, A. Stotland, M. Kritzik, G. Liu, M. Flodstrom-Tullberg, Y.-Q. Zhang, and N. Sarvetnick
The stromal cell-derived factor-1{alpha}/CXCR4 ligand-receptor axis is critical for progenitor survival and migration in the pancreas
J. Cell Biol.,
November 24, 2003;
163(4):
859 - 869.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. H. Yang, M. H. Ma, R. A. Vescio, and J. R. Berenson
Overcoming Drug Resistance in Multiple Myeloma: The Emergence of Therapeutic Approaches to Induce Apoptosis
J. Clin. Oncol.,
November 15, 2003;
21(22):
4239 - 4247.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Kirito, T. Watanabe, K.-i. Sawada, H. Endo, K. Ozawa, and N. Komatsu
Thrombopoietin Regulates Bcl-xL Gene Expression through Stat5 and Phosphatidylinositol 3-Kinase Activation Pathways
J. Biol. Chem.,
March 1, 2002;
277(10):
8329 - 8337.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-J. Lataillade, D. Clay, P. Bourin, F. Herodin, C. Dupuy, C. Jasmin, and M.-C. Le Bousse-Kerdiles
Stromal cell-derived factor 1 regulates primitive hematopoiesis by suppressing apoptosis and by promoting G0/G1 transition in CD34+ cells: evidence for an autocrine/paracrine mechanism
Blood,
February 15, 2002;
99(4):
1117 - 1129.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Urbano-Ispizua, E. Carreras, P. Marin, M. Rovira, C. Martinez, F. Fernandez-Aviles, B. Xicoy, J.-C. Hernandez-Boluda, and E. Montserrat
Allogeneic transplantation of CD34+ selected cells from peripheral blood from human leukocyte antigen-identical siblings: detrimental effect of a high number of donor CD34+ cells?
Blood,
October 15, 2001;
98(8):
2352 - 2357.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Majka, A. Janowska-Wieczorek, J. Ratajczak, K. Ehrenman, Z. Pietrzkowski, M. A. Kowalska, A. M. Gewirtz, S. G. Emerson, and M. Z. Ratajczak
Numerous growth factors, cytokines, and chemokines are secreted by human CD34+ cells, myeloblasts, erythroblasts, and megakaryoblasts and regulate normal hematopoiesis in an autocrine/paracrine manner
Blood,
May 15, 2001;
97(10):
3075 - 3085.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Drouet, J. Mathieu, N. Grenier, E. Multon, J.-J. Sotto, and F. Herodin
The Reduction of In Vitro Radiation-Induced Fas-Related Apoptosis in CD34+ Progenitor Cells by SCF, FLT-3 Ligand, TPO, and IL-3 in Combination Resulted in CD34+ Cell Proliferation and Differentiation
Stem Cells,
September 1, 1999;
17(5):
273 - 285.
[Abstract]
[Full Text]
|
|
|
|
|
